CHANGES IN PHARMACOKINETIC PROPERTIES OF ANTIBACTERIAL DRUGS IN CRITICALLY ILL PATIENTS
Critically ill patients are at high risk of developing a life-threatening infection leading to severe shock and, as a consequence, multi-organ failure and even death. Optimal antimicrobial therapy, especially in the first 48 hours, is crucial to increasing patients' chances of survival. However...
Saved in:
Main Authors: | Agnieszka Małgorzata Cios (Author), Anna Wesołowska (Author) |
---|---|
Format: | Book |
Published: |
Polish Pharmaceutical Society,
2020-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population pharmacokinetics of tigecycline in critically ill patients
by: Xiangru Luo, et al.
Published: (2023) -
Pharmacokinetics of Favipiravir in Critically Ill Patients With COVID‐19
by: Kei Irie, et al.
Published: (2020) -
Pharmacokinetics of Haloperidol in Critically Ill Patients: Is There an Association with Inflammation?
by: Letao Li, et al.
Published: (2022) -
Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
by: Noël Zahr, et al.
Published: (2022) -
Cefiderocol in Critically Ill Patients with Multi-Drug Resistant Pathogens: Real-Life Data on Pharmacokinetics and Microbiological Surveillance
by: Christina König, et al.
Published: (2021)